Novo Goes Public With $3.1 Billion Bid to Pressure Ablynx
Danish pharmaceutical company Novo Nordisk A/S offered as much as 2.6 billion euros ($3.1 billion) in cash to acquire Ablynx NV -- its second run at the maker of treatments for rare bleeding disorders ...